Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keverprazan in Treating H. Pylori
NCT06851468Completed
- Sponsor
- Key Laboratory for Gastrointestinal Diseases of Gansu Province
- Start
- Mar 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of keverprazan in Helicobacter pylori infection (2 arms), sponsored by Key Laboratory for Gastrointestinal Diseases of Gansu Province. Primary endpoint: H.pylori eradication rate. Started Mar 2025; status: completed.
02
Drugs
keverprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT06851468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06851468.